Table 4.

Serum antibody levels in representative patients with and without HAHA development during therapy

Pt-IDHAHAaC1C2C3C4C5C6IntM1M2M3M4M5M6
9K322Ab15.616.717.015.714.514.2NA12.910.511.813.713.9NA
HAHA0000000000000
12K322A27.716.117.926.715.314.43.59.412.011.88.89.8NA
HAHA0000000000000
13K322A12.223.221.023.220.617.9NA11.410.713.39.013.9NA
HAHA000000NA000000
66+K322A12.4NA7.415.113.113.312.512.411.014.111.218.6NA
HAHA01.3000000000.8900
69+K322A5.93.817.016.218.315.410.312.711.512.115.816.8NA
HAHA00.7800000000000
112+K322A12.413.912.810.110.87.610.59.313.312.18.46.2NA
HAHA0.723.21.70.840.460.930.82000000
  • Abbreviations: C, induction course; HAHA, human anti-human antibody; Int, intensification phase; K322A, hu14.18K322A; M, maintenance course; NA, not available; Pt-ID, patient identification number.

  • aHAHA levels detected in a bridging ELISA assay with serum obtained at the initiation of the indicated course before therapy. HAHA+ indicates patients with >0.7 OD unit increase at any time, as compared with the baseline C1 sample. The three patients who experienced a HAHA response at any time are shown. Three representative patients (of 40) without a HAHA response are also shown.

  • bK322A concentration (μg/mL) per indicated course, obtained 1 hour after completion of K322A infusion on day 1 of that course.